Abstract
Current standard treatments for cancer are associated with major dose-limiting toxic effects on healthy tissue. The mucosal layers of the body are particularly sensitive to regimen-induced damage, with patients suffering many unpleasant and potentially life-threatening side-effects. In recent years, there has been an increase in the understanding of the pathobiology of regimen-related mucosal injury which has lead to a number of exciting inventions for its prevention and treatment being recently patented. Agents such as growth factors, cytokines, receptor agonists/antagonists and antiinflammatory agents are among those in development in this emerging field. The complexity of mucosal injury poses a challenge for researchers, however rational targeting of intervention strategies to critical mechanisms will lead to further progress.
Keywords: Mucosal injury, mucositis, chemotherapy, radiotherapy, inflammation, apoptosis, growth factor, intestine, oral
Recent Patents on Anti-Cancer Drug Discovery
Title: Prevention and Treatment of Regimen-Related Mucosal Toxicity
Volume: 3 Issue: 2
Author(s): Joanne M. Bowen
Affiliation:
Keywords: Mucosal injury, mucositis, chemotherapy, radiotherapy, inflammation, apoptosis, growth factor, intestine, oral
Abstract: Current standard treatments for cancer are associated with major dose-limiting toxic effects on healthy tissue. The mucosal layers of the body are particularly sensitive to regimen-induced damage, with patients suffering many unpleasant and potentially life-threatening side-effects. In recent years, there has been an increase in the understanding of the pathobiology of regimen-related mucosal injury which has lead to a number of exciting inventions for its prevention and treatment being recently patented. Agents such as growth factors, cytokines, receptor agonists/antagonists and antiinflammatory agents are among those in development in this emerging field. The complexity of mucosal injury poses a challenge for researchers, however rational targeting of intervention strategies to critical mechanisms will lead to further progress.
Export Options
About this article
Cite this article as:
Bowen M. Joanne, Prevention and Treatment of Regimen-Related Mucosal Toxicity, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489208784638802
DOI https://dx.doi.org/10.2174/157489208784638802 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design NF-κB Signature on the Aging Wall
Current Drug Metabolism Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design The Role of IL-27 and its Receptor in the Pathogenesis of HIV/AIDS and Anti-viral Immune Response
Current HIV Research Emerging Endocrine Therapies in the Treatment of HR-Positive Metastatic Breast Cancer
Current Cancer Therapy Reviews CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Protein & Peptide Letters Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety 3D-QSAR Studies of HDAC6 Inhibitors Using Docking-Based Alignment
Letters in Drug Design & Discovery Synthesis, Characterization and Evaluation of Cytotoxicity of New Aminophosphonic Acid Diesters in Human Leukemia Cells
Letters in Drug Design & Discovery Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis
Current Genomics Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry HIV Protease Inhibitors Impact on Apoptosis
Medicinal Chemistry Daclizumab: A Potential Asthma Therapy?
Recent Patents on Inflammation & Allergy Drug Discovery The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets